Cart
sales@molnova.com
Home - Products - Tyrosine Kinase - BTK - Larotinib

Larotinib

CAS No. 1438072-11-7

Larotinib( —— )

Catalog No. M36515 CAS No. 1438072-11-7

Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 112 Get Quote
5MG 170 Get Quote
10MG 258 Get Quote
25MG 426 Get Quote
50MG 609 Get Quote
100MG 835 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Larotinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
  • Description
    Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK | Tyrosine Kinases | IRAK | EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1438072-11-7
  • Formula Weight
    488.94
  • Molecular Formula
    C24H26ClFN4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C=1C2=C(C=C(OC)C(OCCCN3C[C@@]4([C@](C3)(OCCO4)[H])[H])=C2)N=CN1)C5=CC(Cl)=C(F)C=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu J, et al. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol. 2021 Feb 18;12:636324.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • KS-99

    KS-99 (KS99)?is a novel dual inhibitor of BTK and tubulin polymerization.

  • Fenebrutinib

    An orally bioavailable, selective, non-covalent and reversible BTK inhibitor with IC50 of 2-9 nM.

  • TAK-020

    TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.

Sign In Join Free